Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study.

@article{Vogelmeier2016EfficacyAS,
  title={Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study.},
  author={Claus F Vogelmeier and Pier Luigi Paggiaro and Jordi Dorca and Pawel Śliwiński and Marcel Mallet and A M Kirsten and J. Beier and Beatriz Seoane and Rosa Maria Segarra and Anne R Leselbaum},
  journal={The European respiratory journal},
  year={2016},
  volume={48 4},
  pages={
          1030-1039
        }
}
The efficacy and safety of twice-daily aclidinium bromide/formoterol fumarate was compared with that of salmeterol/fluticasone propionate in patients with stable, moderate-to-severe chronic obstructive pulmonary disease (COPD).AFFIRM COPD (Aclidinium and Formoterol Findings in Respiratory Medicine COPD) was a 24-week, double-blind, double-dummy, active-controlled study. Patients were randomised (1:1) to aclidinium/formoterol 400/12 µg twice-daily via Genuair/Pressair or salmeterol/fluticasone… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 5 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study

International journal of chronic obstructive pulmonary disease • 2018

Inhaled therapies in patients with moderate COPD in clinical practice: current thinking

International journal of chronic obstructive pulmonary disease • 2018
View 1 Excerpt

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

International journal of chronic obstructive pulmonary disease • 2018
View 2 Excerpts

Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review

International journal of chronic obstructive pulmonary disease • 2017
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Evaluation of the psychometric properties of the early morning symptoms of COPD instrument (EMSCI)

M Mocarski, A Hareendran, MH Jen
Value Health • 2014

Similar Papers

Loading similar papers…